Mi az ára Novo Nordisk A/S (NOVO-B)

Novo Nordisk A/S (NOVO-B) ára $44.42

Mi a Novo Nordisk A/S (NOVO-B piaci tőkésítése)

Novo Nordisk A/S piaci tőkésítése (NOVO-B) $197.32B

Novo Nordisk A/S (NOVO-B) Működési Eredményhányad

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Év	Működési árrés	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Működési árrés

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Működési árrés	Működési árrés különbség	Ország
Eli Lilly and Company LLY.US	43.92%	-98.96%	US
Johnson & Johnson JNJ.US	26.81%	-99.36%	US
AbbVie Inc. ABBV.US	29.32%	-99.30%	US
Roche Holding AG RO.SW	26.59%	-99.37%	CH
Merck & Co., Inc. MRK.US	16.65%	-99.60%	US

Vállalat

Működési árrés

Működési árrés különbség

Ország